We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy
Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
AI-guided target identification is now mandatory in London's pharma R&D pipelines, compressing lead optimisation to 14 months and pushing Phase 1 success rates above 80%. Read on.
By James Whitfield, Manufacturing & Supply Chain Writer
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…
By Dr. Eleanor Vance, Regulatory Affairs Editor
The Janus kinase family comprises four intracellular tyrosine kinases JAK1, JAK2, JAK3, and TYK2 that transduce signals from a broad range of cytokine receptors to downstream transcription factors, principally the signal transducer and activator of transcription (STAT) proteins.…
By Dr. Eleanor Vance, Regulatory Affairs Editor
GLP-1 receptor agonists reduce cardiovascular risk through overlapping receptor-mediated and metabolic mechanisms. Explore the trial evidence and biology behind the benefit.
By Dr. Eleanor Vance, Regulatory Affairs Editor
For most licensed medicines that reach the NHS in England, the route to routine clinical use runs through the NICE single technology appraisal (STA) process: a structured assessment of clinical and cost-effectiveness that applies a cost-per-quality-adjusted-life-year (QALY)…
By Dr. Eleanor Vance, Regulatory Affairs Editor
DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?
By Tom Okafor, Clinical Trials Correspondent
The MHRA has granted first-in-world approval for belantamab mafodotin combination regimens in relapsed myeloma, supported by landmark DREAMM-7 and DREAMM-8 Phase 3 trial data.
By Megan Liu, Digital Health Reporter
Most UK medical cannabis products are unlicensed specials. Here is how they are made, imported, regulated and dispensed under a traceable, accountable supply chain.
By James Whitfield, Manufacturing & Supply Chain Writer
The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.
By Tom Okafor, Clinical Trials Correspondent
Liquid biopsies NHS pilot tests multi-cancer early detection to reshape screening pathways and achieve 75% Stage I-II cancer diagnosis by 2028.
By Megan Liu, Digital Health Reporter
The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifyin
By Dr. Eleanor Vance, Regulatory Affairs Editor
The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c
By Tom Okafor, Clinical Trials Correspondent
Subscribe to our weekly pharmaceutical intelligence digest